"iDoctor – Medical Blog"

WASHINGTON (MedPage Today) — The FDA is reviewing safety data from an ongoing trial of the asthma drug omalizumab (Xolair) after interim results showed an excess of cardiovascular and cerebrovascular events among patients taking the drug.

This entry was posted on Friday, July 17th, 2009 at 3:15 am and is filed under Health news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.